Glycolipid antigen induces long-term natural killer T cell anergy in mice

Journal of Clinical Investigation

Volumn 115, Issue 9, 2005, Pages 2572-2583

  Parekh, Vrajesh V ^a   Wilson, Michael T ^a   Olivares Villagómez, Danyvid ^a   Singh, Avneesh K ^a   Wu, Lan ^a   Wang, Chyung Ru ^b   Joyce, Sebastian ^a   Van Kaer, Luc ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; CYTOKINE; GAMMA INTERFERON; GLYCOLIPID; GLYCOPROTEIN; INTERLEUKIN 12P70; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CLONAL ANERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION; THYMUS;

ANIMALS; CLONAL ANERGY; FEMALE; GALACTOSYLCERAMIDES; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKIN-4; KILLER CELLS, NATURAL; LIVER; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; SPLEEN;

EID: 24644433401     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI24762     Document Type: Article

References (53)

1. Bendelac, A., Rivera, M.N., Park, S.H., and Roark, J.H. 1997. Mouse CD1-specific NK1 T cells: development, specificity, and function [review]. Annu. Rev. Immunol. 15:535-562.
2. Godfrey, D.I., Hammond, K.J., Poulton, L.D., Smyth, M.J., and Baxter, A.G. 2000. NKT cells: facts, functions and fallacies [review]. Immunol. Today. 21:573-583.
3. Joyce, S. 2001. CD1d and natural T cells: how their properties jump-start the immune system [review]. Cell. Mol. Life Sci. 58:442-469.
4. Kronenberg, M., and Gapin, L. 2002. The unconventional lifestyle of NKT cells. Nat. Rev. Immunol. 2:557-568.
5. Taniguchi, M., Harada, M., Kojo, S., Nakayama, T., and Wakao, H. 2003. The regulatory role of Vα4 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21:483-513.
6. Brigl, M., and Brenner, M.B. 2004. CD1: antigen presentation and T cell function [review]. Annu. Rev. Immunol. 22:817-890.
7. Van Kaer, L. 2004. Regulation of immune responses by CD1d-restricted natural killer T cells. Immunol. Res. 30:139-153.
8. Godfrey, D.I., and Kronenberg, M. 2004. Going both ways: immune regulation via CD1d-dependent NKT cells [review]. J. Clin. Invest. 114:1379-1388. doi:10.1172/JCI200522452.
9. Natori, T., Koezuka, Y., and Higa, T. 1993. Agelasphins, novel α-galactosylceramides from the marine sponge Agelas mauritianus. Tetrahedron Lett. 34:5591-5592.
10. Hong, S., et al. 2001. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 7:1052-1056.
11. Sharif, S., et al. 2001. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat. Med. 7:1057-1062.
12. Wang, B., Geng, Y. B., and Wang, C. R. 2001. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J. Exp. Med. 194:313-320.
13. Naumov, Y.N., et al. 2001. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc. Natl. Acad. Sci. U. S. A. 98:13838-13843.
14. Singh, A.K., et al. 2001. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194:1801-1811.
15. Jahng, A.W., et al. 2001. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. 194:1789-1799.
16. Miyamoto, K., Miyake, S., and Yamamura, T. 2001. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature. 413:531-534.
17. Osman, Y., et al. 2000. Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide. Eur. J. Immunol. 30:1919-1928.
18. Ito, K., et al. 2000. Involvement of decidual Vα14 NKT cells in abortion. Proc. Natl. Acad. Sci. U. S. A. 97:740-744.
19. Major, A.S., and Van Kaer, L. 2005. The role of natural killer T cells in atherosclerosis. Current Immunology Reviews. In press.
20. Singh, N., et al. 1999. Cutting edge: activation of NK T cells by CD1d and α-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J. Immunol. 163:2373-2377.
21. Fujii, S., Shimizu, K., Kronenberg, M., and Steinman, R.M. 2002. Prolonged IFN-γ-producing NKT response induced with α- galactosylceramide-loaded DCs. Nat. Immunol. 3:867-874.
22. Matsuda, J.L., et al. 2003. Mouse Vα4i natural killer T cells are resistant to cytokine polarization in vivo. Proc. Natl. Acad. Sci. U. S. A. 100:8395-8400.
23. Eberl, G., and MacDonald, H.R. 1998. Rapid death and regeneration of NKT cells in and-CD3epsilon-or IL-12-treated mice: a major role for bone marrow in NKT cell homeostasis. Immunity. 9:345-353.
24. Eberl, G., and MacDonald, H.R. 2000. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur. J. Immunol. 30:985-992.
25. Leite-de-Moraes, M.C., et al. 2000. Fas/Fas ligand interactions promote activation-induced cell death of NKT lymphocytes. J. Immunol. 165:4367-4371.
26. Wilson, M.T., et al. 2003. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc. Natl. Acad. Sci. U. S. A. 100:10913-10918.
27. Crowe, N.Y., et al. 2003. Glycolipid antigen drives rapid expansion and sustained cytokine production by NKT cells. J. Immunol. 171:4020-4027.
28. Harada, M., et al. 2004. Down-regulation of the invariant Vα14 antigen receptor in NKT cells upon activation. Int. Immunol. 16:241-247.
29. Burdin, N., Brossay, L., and Kronenberg, M. 1999. Immunization with α-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur. J. Immunol. 29:2014-2025.
30. Schwartz, R.H. 2003. T cell anergy. Annu. Rev. Immunol 21:305-334.
31. Matsuda, J.L., et al. 2000. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192:741-754.
32. Hayakawa, Y., Berzins, S.P., Crowe, N.Y., Godfrey, D.I., and Smyth, M.J. 2004. Antigen-induced tolerance by intrathymic modulation of self-recognizing inhibitory receptors. Nat. Immunol. 5:590-596.
33. Benlagha, K., Kyin, T., Beavis, A., Teyton, L., and Bendelac, A. 2002. A thymic precursor to the NKT cell lineage. Science. 296:553-555.
34. + CD1d-dependent precursor stage. J. Exp. Med. 195:835-844.
35. Parekh, V.V., et al. 2004. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct α- and β-anomeric glycolipids. J. Immunol. 173:3693-3706.
36. Carnaud, C., et al. 1999. Cutting edge: crosstalk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163:4647-4650.
37. Wilson, M.T., and Van Kaer, L. 2003. Natural killer T cells as targets for therapeutic intervention in autoimmune diseases. Curr. Pharm. Des. 9:201-220.
38. Steinman, R.M., Hawiger, D., and Nussenzweig, M.C. 2003. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21:685-711.
39. + suppressor T cells: more questions than answers [review]. Nat. Rev. Immunol. 2:389-400.
40. Bezbradica, J.S., et al. 2005. Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J. Immunol. 174:4694-4705.
41. Ota, T., et al. 2005. IFN-γ-mediated negative feedback regulation of NKT cell function by CD94/NKG2. Blood. 106:184-192.
42. Webb, S., Morris, C., and Sprent, J. 1990. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell. 63:1249-1256.
43. a expressing cells. Nature. 339:541-544.
44. Hildeman, D.A., Zhu, Y., Mitchell, T.C., Kappler, J., and Marrack, P. 2002. Molecular mechanisms of activated T cell death in vivo. Curr. Opin. Immunol. 14:354-359.
45. Li, H., Llera, A., Malchiodi, E.L., and Mariuzza, R.A. 1999. The structural basis of T cell activation by superantigens. Annu. Rev. Immunol. 17:435-466.
46. Wilson, M.T., Singh, A.K., and Van Kaer, L. 2002. Immunotherapy with ligands of natural killer T cells. Trends Mol. Med. 8:225-231.
47. Van Kaer, L. 2005. α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles [review]. Nat. Rev. Immunol. 5:31-42.
48. Fujii, S., Shimixu, K., Smith, C., Bonifaz, L., and Steinman, R.M. 2003. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198:267-279.
49. + T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J. Immunol. 171:5140-5147.
50. Mendiratta, S.K., et al. 1997. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity. 6:469-477.
51. + T cells. Cell 71:1205-1214.
52. Cui, J., et al. 1997. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science. 278:1623-1626.
53. Stanic, A.K., et al. 2003. Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by β-D-glucosylceramide synthase deficiency. Proc. Natl. Acad. Sci. U. S. A. 100:1849-1854.